GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: MetMAb | OA-5D5 | OA5D5 | PRO 143966
Compound class:
Antibody
Comment: Onartuzumab is an investigational, humanized monoclonal antibody targeting the MET receptor tyrosine kinase, a proto-oncogene which acts as a hepatocyte growth factor receptor. The protein is a monovalent (single-armed) construct, as opposed to bi-valent intact antibody structures.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. BLAST peptide analysis reveals identical match with sequences deposited with patent US7615529 [4], which relate to the monoclonal isolated from hybridoma 5D5.11.6 therein. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 9368 | onartuzumab |
| Synonyms |
| MetMAb | OA-5D5 | OA5D5 | PRO 143966 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 368 |
| Other databases | |
| GtoPdb PubChem SID | 310264746 |
| Search PubMed clinical trials | onartuzumab |
| Search PubMed titles | onartuzumab |
| Search PubMed titles/abstracts | onartuzumab |
